You seem to be worried about this calcium problem too. It does seem to be an issue. Hmmmmm.
I think we just focus on making sure the humans in the upcoming phase 1 trial REALLY like cheese. That worked for the mice. So we already know that NYR is valued at $45billion for TBI, $52billion for stroke, $244b for hypertension, and also $442b for toenails now, already proven.
If we have to factor out lactose intolerant people from treatment, we are only left with a market cap north of $35 trillion dollars. Does that impact your forecasts?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.03M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1642 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 682527 | 2 |
View Market Depth
| Last trade - 14.40pm 31/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |
Day chart unavailable